Added to YB: 2025-05-08
Pitch date: 2025-05-06
NVO [bullish]
Novo Nordisk A/S
-26.33%
current return
Author Info
I write about investing, decision-making, and the power of compounding in both wealth and life. My focus is on rational investing, long-term thinking, and avoiding the emotional traps that derail most investors. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 435.90
Price Target
861.00 (+168%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Novo Nordisk – A Victim of Its Own Hype
NVO: Obesity drug leader at attractive P/E, with 22% YoY revenue growth. CagriSema trial disappointed (13.7% vs expected 15% weight loss), causing 60% drop. Market misinterpreting competition - obesity isn't winner-takes-all. DCF shows 11-15% FCF growth needed to justify price. Headwinds: Eli Lilly gaining share, compounders (30-40% market), pricing pressure. Catalysts: FDA ending compounding exceptions, Hims partnership.
Read full article (11 min)